No Data
No Data
Livzon Pharma (01513) spent approximately 5.4011 million yuan to buy back 0.153 million shares of A-shares on September 18th.
Livzon Pharma (01513) announced that on September 18, 2024, it spent approximately 5.4011 million yuan to repurchase 15.3...
Will Weakness in Livzon Pharmaceutical Group Inc.'s (SZSE:000513) Stock Prove Temporary Given Strong Fundamentals?
Livzon Pharmaceutical Group Inc. expects reduced performance pressure in the second half of the year | Live coverage of the earnings conference
① At the results meeting, Yang Liang, director of Lizhu Group, responded to issues such as the year-on-year decline in the company's revenue and financial data in various segments; ② Tang Yanggang, president of the company, said that the overall market size of tocilizumab injections in China is small.
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
Founder Securities: the revenue growth rate of the pharmacy sector slows down, and the concentration is expected to accelerate.
The individual account reform of medical insurance has led to a decrease in personal account income, affecting pharmaceutical sales and pharmacy business relying on individual account payments. In 2023, pharmacy medical insurance personal account expenditures decreased by 9%, and this trend is expected to continue in 2024.
Livzon Pharmaceutical Group Inc. (000513.SZ): has repurchased 0.62% of its shares.
On September 2, Gelonghui reported that Livzon Pharmaceutical Group Inc. (000513.SZ) announced that as of August 31, 2024, the company has repurchased a total of 5,704,200 A-shares through centralized bidding trading, accounting for 0.62% of the total share capital. The highest purchase price was RMB 36.80 per share, and the lowest purchase price was RMB 32.95 per share. The total amount of funds used was RMB 200,208,770.00 (excluding transaction costs). The repurchase complies with the company's established share repurchase plan.
No Data
No Data